TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25924098

Group type: EXPERIMENTAL
Intervention: Active TENS with positive expectations
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Active TENS with neutral expectations
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Active TENS with negative expectations
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo TENS with positive expectations
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo TENS with neutral expectations
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo TENS with negative expectations
Number of subjects: 161
Study: 24906579

Group type: EXPERIMENTAL
Intervention: Autogenic Training (AT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (Physiotherapy alone)
Number of subjects: 66
Study: 22244510

Group type: EXPERIMENTAL
Intervention: Patellar tendon graft
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Hamstring graft
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 20190541

Group type: EXPERIMENTAL
Intervention: Thyroxine treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 50
Study: 18552701

Group type: EXPERIMENTAL
Intervention: Endoscopic surgery (Group A, n = 113)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Conservative treatment (Group B, n = 113)
Number of subjects: 226
Study: 15776337

Group type: EXPERIMENTAL
Intervention: Backward run/walk training program for six weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group restricted to daily activities
Number of subjects: 26
Study: 12434840

Group type: EXPERIMENTAL
Intervention: Processing of psalm-type words (silent letter condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Processing of pasta-type words (nonsilent letter condition)
Number of subjects: 0
Study: 10622543

Group type: EXPERIMENTAL
Intervention: Papaverine injection
Number of subjects: 75

Group type: COMPARATOR
Intervention: Isotonic saline injection
Number of subjects: 75

Group type: COMPARATOR
Intervention: No injection
Number of subjects: 75
Study: 7782057

Group type: EXPERIMENTAL
Intervention: Purified urinary follicle‐stimulating hormone (uFSH‐HP; Metrodin HP®) in standard IVF
Number of subjects: 11

Group type: COMPARATOR
Intervention: Combination of pure FSH and human menopausal gonadotrophin (hMG; Pergonal®) in standard IVF
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Recombinant FSH (Gonal F®) in ICSI
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Standard IVF vs ICSI
Number of subjects: 11
Study: 2209234

Group type: EXPERIMENTAL
Intervention: Defibrase (DF) 0.05 u or 0.075 u/kg over 1 hour immediately after the attack and 0.025 u/kg over 4 hours on the 5th and 10th day
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional therapy only
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Defibrase (DF)
Number of subjects: 21
Study: 446284

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 31442498

Group type: EXPERIMENTAL
Intervention: Esophagectomy alone
Number of subjects: 13365

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 13365

Group type: EXPERIMENTAL
Intervention: Optimal therapy (predicted)
Number of subjects: 13365

Group type: EXPERIMENTAL
Intervention: Actual therapy received
Number of subjects: 13365
Study: 30139336

Group type: EXPERIMENTAL
Intervention: Community coaching by Extension Educators/field staff, FPC development, and development of a MyChoice food pantry (intervention group).
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison group (no community coaching).
Number of subjects: 24
Study: 26840852

Group type: EXPERIMENTAL
Intervention: Multicomponent ACP intervention program (integrating motivational interviewing, evidence‐based ACP facilitation program, and health‐literacy adjusted AD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Educational material (control group)
Number of subjects: 30
Study: 24507657

Group type: COMPARATOR
Intervention: TRO40303 (0.5 to 13 mg/kg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 20676646

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate injection (SH)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Physical therapy modalities (PTM)
Number of subjects: 24
Study: 20179559

Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.2 mg/kg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 17331930

Group type: EXPERIMENTAL
Intervention: 500 mL 6% hydroxyethyl starch (HES)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1500 mL lactated Ringer's (LR)
Number of subjects: 30
Study: 16392462

Group type: EXPERIMENTAL
Intervention: Written exercise sheet (Group 1)
Number of subjects: 64

Group type: COMPARATOR
Intervention: No exercise sheet (Group 2)
Number of subjects: 64
Study: 12020186

Group type: EXPERIMENTAL
Intervention: Community pharmacist intervention (education, brochure on risk factors, point-of-care cholesterol measurement, referral to physician, regular follow-up for 16 weeks)
Number of subjects: 675

Group type: COMPARATOR
Intervention: Usual care (brochure and general advice only, minimal follow-up)
Number of subjects: 675
Study: 11675809

Group type: EXPERIMENTAL
Intervention: Workbook intervention
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Computer intervention
Number of subjects: 376

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 376
Study: 9731025

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 271
Study: 7846196

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg IV as a 3-min infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg orally
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zolpidem 5 mg IV
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zolpidem 5 mg orally
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2454514

Group type: EXPERIMENTAL
Intervention: Prostacyclin 5 ng kg‐1 min‐1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Iloprost 2 ng kg‐1 min‐1
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 1204500

Group type: EXPERIMENTAL
Intervention: Attenuated influenza-A-virus strain 'Alice' (H3N2), given intransally in drops (10(7,2) ID50 per dose), twice seven days apart
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Attenuated influenza-A-virus strain 'Alice' (H3N2)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Inactivated virus vaccine
Number of subjects: 25
Study: 30553764

Group type: EXPERIMENTAL
Intervention: CHO‐BD
Number of subjects: 11

Group type: COMPARATOR
Intervention: CHO
Number of subjects: 11
Study: 28301620

Group type: EXPERIMENTAL
Intervention: CeraVe Itch Relief Lotion and Cream (1% pramoxine hydroxide)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: CeraVe Itch Relief Cream (1% pramoxine hydrochloride)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Hydrocortisone 1% cream
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: CeraVe Itch Relief Cream (1% pramoxine hydrochloride) used daily over 6 days
Number of subjects: 66
Study: 25082954

Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Low energy diet (LED)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both AIT and LED
Number of subjects: 70
Study: 23329885

Group type: EXPERIMENTAL
Intervention: Guanidinoacetic acid (GAA) 2.4 grams daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 24
Study: 22077689

Group type: EXPERIMENTAL
Intervention: CEM (Calcium-Enriched Mixture)
Number of subjects: 40

Group type: COMPARATOR
Intervention: MTA (Mineral Trioxide Aggregate)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CEM
Number of subjects: 40

Group type: COMPARATOR
Intervention: MTA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CEM and MTA
Number of subjects: 40
Study: 19806264

Group type: EXPERIMENTAL
Intervention: rFXIII-A(2) (11.9, 25, 35 or 50 IU/kg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: rFXIII-A(2) (35 IU/kg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: rFXIII-A(2) (25-50 IU/kg)
Number of subjects: 43
Study: 16397287

Group type: EXPERIMENTAL
Intervention: Sirolimus tablet
Number of subjects: 477

Group type: COMPARATOR
Intervention: Sirolimus solution
Number of subjects: 477
Study: 14965840

Group type: EXPERIMENTAL
Intervention: Hemoperfusion plus hemodialysis (HP+HD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hemodialysis (HD)
Number of subjects: 40
Study: 11342952

Group type: EXPERIMENTAL
Intervention: No dressing
Number of subjects: 120

Group type: COMPARATOR
Intervention: Adhesive biomembrane dressing
Number of subjects: 120

Group type: COMPARATOR
Intervention: Compressive wrap dressing
Number of subjects: 120
Study: 9170048

Group type: EXPERIMENTAL
Intervention: Breath-holding after breathing room air
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Breath-holding after hyperventilation of room air
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Breath-holding after O2 administration
Number of subjects: 118
Study: 8223829

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3536677

Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole 500 mg eight hourly (19 patients)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Identical intravenous placebo (20 patients)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole
Number of subjects: 39

Group type: COMPARATOR
Intervention: Identical intravenous placebo
Number of subjects: 39
Study: 31673234

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 64
Study: 30019181

Group type: EXPERIMENTAL
Intervention: Within school schedule intervention group
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: After-school intervention group
Number of subjects: 837

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 837
Study: 27097575

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aerosol (flixotide)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Budesonide suspension
Number of subjects: 214

Group type: COMPARATOR
Intervention: Control group (no regular inhalation of corticosteroid)
Number of subjects: 214
Study: 24449009

Group type: EXPERIMENTAL
Intervention: Low-frequency noise band (0.375-0.75 kHz)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: High-frequency noise band (2.25-4.5 kHz)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Minimum audible angle (MAA) thresholds
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Localization accuracy
Number of subjects: 2
Study: 22077816

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 12944

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12944
Study: 19945103

Group type: EXPERIMENTAL
Intervention: Uterine artery ligation
Number of subjects: 103

Group type: COMPARATOR
Intervention: Pericervical tourniquet
Number of subjects: 103
Study: 17490672

Group type: EXPERIMENTAL
Intervention: 2 ng/kg LPS intravenously
Number of subjects: 36

Group type: COMPARATOR
Intervention: Physiologic saline solution (placebo)
Number of subjects: 36
Study: 15550496

Group type: COMPARATOR
Intervention: 5.0 mm conventional instruments
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 3.5 mm mini-instruments
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Vaginal deliveries
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Experienced surgeons
Number of subjects: 480
Study: 12499334

Group type: EXPERIMENTAL
Intervention: Vitamin A (retinyl palmitate) added to corn bread
Number of subjects: 5

Group type: COMPARATOR
Intervention: Corn bread served with water
Number of subjects: 5

Group type: COMPARATOR
Intervention: Corn bread served with coffee
Number of subjects: 5
Study: 11220545

Group type: EXPERIMENTAL
Intervention: Medtronic Kappa 700(Europe)/Kappa 400(North America) pacemaker
Number of subjects: 0

Group type: COMPARATOR
Intervention: Implantable loop recorder (ILR)
Number of subjects: 0
Study: 8594515

Group type: EXPERIMENTAL
Intervention: Brovincamine fumarate (20 mg 3 times daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (3 times daily)
Number of subjects: 28
Study: 2015119

Group type: EXPERIMENTAL
Intervention: Group aerobic exercise training
Number of subjects: 308

Group type: COMPARATOR
Intervention: Group light exercise
Number of subjects: 308
Study: 6961759

Group type: EXPERIMENTAL
Intervention: Labetalol 200 mg daily
Number of subjects: 24
Study: 3907824

Group type: EXPERIMENTAL
Intervention: Metoclopramide 60 mg
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Metoclopramide 120 mg
Number of subjects: 112

Group type: COMPARATOR
Intervention: Cisplatin treatment
Number of subjects: 112
Study: 29850782

Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine combination therapy (80/5 mg) for 16 weeks
Number of subjects: 23
Study: 27444761

Group type: EXPERIMENTAL
Intervention: Lidocaine jelly
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Betamethasone gel
Number of subjects: 99

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 99
Study: 24950172

Group type: EXPERIMENTAL
Intervention: Guilt-inducing condition (game play as a terrorist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (game play as a UN soldier)
Number of subjects: 0
Study: 22789773

Group type: EXPERIMENTAL
Intervention: Video-based therapy at home for patients with stroke (3 months duration)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional therapy (weekly outpatient therapy sessions)
Number of subjects: 90
Study: 20565152

Group type: EXPERIMENTAL
Intervention: Web-based personalized feedback intervention
Number of subjects: 341

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 341
Study: 18386569

Group type: EXPERIMENTAL
Intervention: Allicin via gastroscopy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 80
Study: 16644783

Group type: COMPARATOR
Intervention: Infliximab (16 weeks)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Etanercept (12 weeks)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Pooled indices (DAS and DAS28)
Number of subjects: 164
Study: 11445622

Group type: EXPERIMENTAL
Intervention: nicardipine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 14
Study: 9817115

Group type: EXPERIMENTAL
Intervention: Belgian Dutch translation of the SF-36 Health Survey
Number of subjects: 4448

Group type: EXPERIMENTAL
Intervention: Belgian French translation of the SF-36 Health Survey
Number of subjects: 4448

Group type: EXPERIMENTAL
Intervention: SF-36 scale scores
Number of subjects: 4448

Group type: EXPERIMENTAL
Intervention: Change in SF-36 scale scores over 6 months
Number of subjects: 4448

Group type: EXPERIMENTAL
Intervention: French-speaking patients
Number of subjects: 4448

Group type: EXPERIMENTAL
Intervention: Average change in SF-36 scale scores
Number of subjects: 4448
Study: 8061995

Group type: EXPERIMENTAL
Intervention: Supine lateral dual X‐ray absorptiometry (DXA) with baseline compensation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Supine lateral dual X‐ray absorptiometry (DXA) without baseline compensation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Supine lateral dual X‐ray absorptiometry (DXA) with multiplicative algorithm
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Supine lateral dual X‐ray absorptiometry (DXA) for L2‐L4
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Supine lateral dual X‐ray absorptiometry (DXA) for individual vertebrae
Number of subjects: 12
Study: 3354802

Group type: EXPERIMENTAL
Intervention: Caudal injection of 1 ml/kg bupivacaine 0.25%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wound infiltration of 0.5 ml/kg bupivacaine 0.25%
Number of subjects: 50
Study: 28800141

Group type: COMPARATOR
Intervention: Ketoconazole
Number of subjects: 88

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 88
Study: 27486141

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24-48 IU/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 25136015

Group type: EXPERIMENTAL
Intervention: GSK1322322 at 1,500 mg b.i.d.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Linezolid at 600 mg b.i.d.
Number of subjects: 75
Study: 23174463

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy group (IPT-G)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Creative play/recreation group
Number of subjects: 304

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 304
Study: 20517868

Group type: EXPERIMENTAL
Intervention: Human Albumin Grifols 5%
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study: 18452826

Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen (PSA) screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of PSA with other markers or tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational studies of PSA benefit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer models for inferring impact of screening
Number of subjects: 0
Study: 16292207

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetuximab for pretreated colorectal cancer
Number of subjects: 0
Study: 11866009

Group type: EXPERIMENTAL
Intervention: Nacystelyn (NAL) 24 mg (12 puffs)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (12 puffs)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nacystelyn (NAL) (4 mg to 16 mg, varying doses)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 10212885

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 26
Study: 8829889

Group type: EXPERIMENTAL
Intervention: Aceclofenac (100 mg b.i.d.)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Diclofenac (50 mg t.i.d.)
Number of subjects: 343
Study: 2221301

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Piritramid-diazepam
Number of subjects: 40
Study: 326265

Group type: EXPERIMENTAL
Intervention: Ditenate Tetra (combination of tetracycline, theophylline, doxylamine succinate, etafedrine, phenylephrine, and guaifenesine)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 29275919

Group type: EXPERIMENTAL
Intervention: 10 mg melatonin (2 melatonin capsules, 5 mg each)
Number of subjects: 60
Study: 30372693

Group type: EXPERIMENTAL
Intervention: Phyllanthus niruri
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 26743734

Group type: EXPERIMENTAL
Intervention: Endovascular stenting for CoA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study: 24733476

Group type: EXPERIMENTAL
Intervention: Amodiaquine plus sulfadoxine‐pyrimethamine (AQ/SP)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin plus piperaquine (DP)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group (no SMC)
Number of subjects: 360
Study: 23259658

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 486
Study: 20007932

Group type: EXPERIMENTAL
Intervention: CPAP treatment (n = 178)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Conservative treatment (n = 181)
Number of subjects: 359
Study: 17418425

Group type: EXPERIMENTAL
Intervention: Submucosal resection (SR)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Microdebrider-assisted inferior turbinoplasty (MAIT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Both SR and MAIT
Number of subjects: 120
Study: 16466277

Group type: EXPERIMENTAL
Intervention: Withdrawal of pulmonary artery catheters (PACs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Use of pulmonary artery catheters (PACs)
Number of subjects: 0
Study: 12152002

Group type: EXPERIMENTAL
Intervention: 200 mg clarithromycin, 30 mg lansoprazole, and 750 mg amoxicillin for 7 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 400 mg clarithromycin, 30 mg lansoprazole, and 750 mg amoxicillin for 7 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group received 30 mg lansoprazole and 750 mg amoxicillin for 7 days without clarithromycin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: H pylori-positive patients given 400 mg/day clarithromycin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: H pylori-positive patients given 800 mg/day clarithromycin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both patient groups (200 mg and 400 mg clarithromycin)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study: 10527181

Group type: EXPERIMENTAL
Intervention: 5 mg/d of risedronate
Number of subjects: 2458

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2458
Study: 7669481

Group type: EXPERIMENTAL
Intervention: lisinopril 20 mg
Number of subjects: 118

Group type: COMPARATOR
Intervention: hydrochlorothiazide 25 mg
Number of subjects: 118

Group type: COMPARATOR
Intervention: atenolol 100 mg
Number of subjects: 118

Group type: COMPARATOR
Intervention: amlodipine 10 mg
Number of subjects: 118
Study: 2185158

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g daily for 5 days
Number of subjects: 73

Group type: COMPARATOR
Intervention: Oral penicillin 1 million units 3 times daily for 12 days
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 73

Group type: COMPARATOR
Intervention: Oral penicillin
Number of subjects: 73
Study: 6784595

Group type: EXPERIMENTAL
Intervention: Electrostimulation anaesthesia
Number of subjects: 10

Group type: COMPARATOR
Intervention: Neuroleptanesthesia
Number of subjects: 10